|
1
|
Li L, Gao Y, Zhang L, Zeng J, He D and Sun
Y: Silibinin inhibits cell growth and induces apoptosis by caspase
activation, down-regulating survivin and blocking EGFR-ERK
activation in renal cell carcinoma. Cancer Lett. 272:61–69. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Bukowski RM: Natural history and therapy
of metastatic renal cell carcinoma: the role of interleukin-2.
Cancer. 80:1198–1220. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rabinovitch RA, Zelefsky MJ, Gaynor JJ and
Fuks Z: Patterns of failure following surgical resection of renal
cell carcinoma: implications for adjuvant local and systemic
therapy. J Clin Oncol. 12:206–212. 1994.PubMed/NCBI
|
|
5
|
Baaten G, Voogd AC and Wagstaff J: A
systematic review of the relation between interleukin-2 schedule
and outcome in patients with metastatic renal cell cancer. Eur J
Cancer. 40:1127–1144. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhan HL, Gao X, Zhou XF, Pu XY and Wang
DJ: Presence of tumour-infiltrating FOXP3+ lymphocytes
correlates with immature tumour angiogenesis in renal cell
carcinomas. Asian Pac J Cancer Prev. 13:867–872. 2012.PubMed/NCBI
|
|
7
|
Abe H and Kamai T: Recent advances in the
treatment of metastatic renal cell carcinoma. Int J Urol.
20:944–955. 2013.PubMed/NCBI
|
|
8
|
Witters LA: The blooming of the French
lilac. J Clin Invest. 108:1105–1107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruiter R, Visser LE, van Herk-Sukel MP, et
al: Lower risk of cancer in patients on metformin in comparison
with those on sulfonylurea derivatives: results from a large
population-based follow-up study. Diabetes Care. 35:119–124. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: a representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar
|
|
11
|
Wu N, Gu C, Gu H, Hu H, Han Y and Li Q:
Metformin induces apoptosis of lung cancer cells through activating
JNK/p38 MAPK pathway and GADD153. Neoplasma. 58:482–490. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Storozhuk Y, Hopmans SN, Sanli T, et al:
Metformin inhibits growth and enhances radiation response of
non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J
Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fang Z, Tang Y, Fang J, et al: Simvastatin
inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK
and JAK2/STAT3 pathway. PloS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang Z, Tang Y, Jiao W, et al: Nitidine
chloride inhibits renal cancer cell metastasis via suppressing AKT
signaling pathway. Food Chem Toxicol. 60:246–251. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pollak M: Metformin and other biguanides
in oncology: advancing the research agenda. Cancer Prev Res
(Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: a new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
|
|
18
|
Xiong Y, Lu QJ, Zhao J and Wu GY:
Metformin inhibits growth of hepatocellular carcinoma cells by
inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J
Cancer Prev. 13:3275–3279. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goodwin PJ, Ligibel JA and Stambolic V:
Metformin in breast cancer: time for action. J Clin Oncol.
27:3271–3273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okoshi R, Ozaki T, Yamamoto H, et al:
Activation of AMP-activated protein kinase induces p53-dependent
apoptotic cell death in response to energetic stress. J Biol Chem.
283:3979–3987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen MB, Wu XY, Gu JH, Guo QT, Shen WX and
Lu PH: Activation of AMP-activated protein kinase contributes to
doxorubicin-induced cell death and apoptosis in cultured myocardial
H9c2 cells. Cell Biochem Biophys. 60:311–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu J, Li M, Song B, et al: Metformin
inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol
Oncol. 31:264–270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Senderowicz AM: Targeting cell cycle and
apoptosis for the treatment of human malignancies. Curr Opin Cell
Biol. 16:670–678. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schwartz GK and Shah MA: Targeting the
cell cycle: a new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alao JP: The regulation of cyclin D1
degradation: roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song E, Ma X, Li H, et al: Attenuation of
krüppel-like factor 4 facilitates carcinogenesis by inducing g1/s
phase arrest in clear cell renal cell carcinoma. PloS One.
8:e677582013.
|
|
27
|
Laviolette LA, Wilson J, Koller J, et al:
Human folliculin delays cell cycle progression through late S and
G2/M-phases: effect of phosphorylation and tumor associated
mutations. PloS One. 8:e667752013. View Article : Google Scholar
|
|
28
|
Circu ML and Aw TY: Glutathione and
modulation of cell apoptosis. Biochim Biophys Acta. 1823:1767–1777.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andersen JL and Kornbluth S: The tangled
circuitry of metabolism and apoptosis. Mol Cell. 49:399–410. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Petsophonsakul P, Pompimon W and
Banjerdpongchai R: Apoptosis induction in human leukemic
promyelocytic HL-60 and monocytic U937 cell lines by goniothalamin.
Asian Pac J Cancer Prev. 14:2885–2889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smith MA and Schnellmann RG: Calpains,
mitochondria, and apoptosis. Cardiovasc Res. 96:32–37. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hasan TN, BLG, Shafi G, Al-Hazzani AA and
Alshatwi AA: Anti-proliferative effects of organic extracts from
root bark of Juglans Regia L (RBJR) on MDA-MB-231 human
breast cancer cells: role of Bcl-2/Bax, caspases and Tp53. Asian
Pac J Cancer Prev. 12:525–530. 2011.PubMed/NCBI
|
|
34
|
Zhang N, Kong X, Yan S, Yuan C and Yang Q:
Huaier aqueous extract inhibits proliferation of breast cancer
cells by inducing apoptosis. Cancer Sci. 101:2375–2383. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang N, Wang X, Huo Q, et al: The
oncogene metadherin modulates the apoptotic pathway based on the
tumor necrosis factor superfamily member TRAIL (tumor necrosis
factor-related apoptosis-inducing ligand) in breast cancer. J Biol
Chem. 288:9396–9407. 2013. View Article : Google Scholar
|
|
36
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nature Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Himelstein BP, Lee EJ, Sato H, Seiki M and
Muschel RJ: Tumor cell contact mediated transcriptional activation
of the fibroblast matrix metalloproteinase-9 gene: involvement of
multiple transcription factors including Ets and an alternating
purine-pyrimidine repeat. Clin Exp Metastasis. 16:169–177. 1998.
View Article : Google Scholar
|
|
38
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
39
|
Hu Y and Ivashkiv LB: Costimulation of
chemokine receptor signaling by matrix metalloproteinase-9 mediates
enhanced migration of IFN-alpha dendritic cells. J Immunol.
176:6022–6033. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
